ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Leiras Oy, part of Bayer AG, is a company headquartered in Turku, Finland. The firm develops pharmaceutical solutions. It was acquired by Nycomed Pharma Holding An on May 31, 2003 for $49.44 million.

Osteologix is engaged in late stage development of pharmaceutical products for diseases of bone and cartilage. Osteologix is committed to developing innovative pharmaceuticals for the treatment and prevention of diseases of bone and joint tissues. It is our vision to improve the health of those afflicted with musckuloskelatal diseases such as osteoporosis. Our Mission is to partner with the healthcare community to apply new scientific information and clinical data to the development of products that improve patient care in a safe and ethical manner.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. Its products include potassium clavulanate, cyclosporine, tacrolimus, demeclocycline hydrochloride, rifampicin, rifampicin SV sodium, teicoplanin, vancomycin HCL, fumagillin, diquafosol sodium, everolimus, daptomycin, tenofovir disoproxil aspartate, and acarbose. The company was founded on November 12, 2001 and is headquartered in Seoul, South Korea.

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

The Nisshin OilliO Group, Ltd. engages in the manufacture, processing, and distribution of edible oils. It operates through the following segments: Oils and Fats, Modified Fats, Fine Chemicals, Healthy Food and Others. The Oils and Fats segment manufactures and supplies edible oil products for home use, commercial purpose, and food processing. The Modified Fats segment manufactures and supplies modified fats and chocolates. The Fine Chemicals segment manufactures and supplies cosmetic raw materials and chemical substances. The Healthy Food segment manufactures and supplies dressings and mayonnaise. The Others segment deals with temporary staffing, insurance agency, and golf driving range and equipment rental businesses. The company was founded by Kihachiro Okura and Kyujiro Matsushita on February 22, 1907 and is headquartered in Tokyo, Japan.

Asahi Kasei Pharma Corp., a subsidiary of Asahi Kasei Corp., is a company headquartered in Tokyo, Japan, that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

Zhongshan Laibo Ruichen Bio-Pharmaceutical Co., Ltd., established on 2021-01-07, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(The above business scope involves:Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)) (Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Pharmaceutical commissioned production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)[The above business scope does not include:Research and development of rare and unique precious varieties in China,farming,Planting and production of related propagating material(including farming,animal husbandry,Good Genes of Aquaculture);crop,Breeding livestock and poultry,Selection and Breeding of Transgenic Varieties of Aquatic Seedlings and Their Transgenic Seeds(Seedling)Production;Invest in Human Stem Cells,Development and application of genetic diagnosis and treatment technology;Invest in the steaming of Chinese herbal decoction pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines](The above projects do not involve special management measures for foreign investment access)

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

Michi Co. Ltd. engages in the production and sale of nail chips. It conducts its business through the e-commerce site michi nail. The company was founded by Shun Nakazaki on June 25, 2012 and is headquartered in Tokyo, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Manufactures pharmaceuticals and diagnostic substances

Guangdong Anno Pharmaceutical Co., Ltd., established on 2010-09-15, Business scope includes research and development,Production,Sales:tablet,hard capsule,Granules,medical instruments,Healthy food,food;Traditional Chinese medicine pretreatment and extraction workshop,Manufacturing of Smart Home Consumer Devices;Home Appliance Sales;Research and Development of Household Appliances;Household Appliance Manufacturing;Sales of electrical accessories;Import and export;electronics sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jianmin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, wholesale and retail of pharmaceutical products. The company manufactures tablets, hard capsules, granules, pills, syrup, powder, decoction, wine, and mixture, beverages, health foods, and cosmetics. It also provides Chinese medicine diagnosis and treatment services. The company was founded on June 1, 1953 and is headquartered in Wuhan, China.

Anhui Shanhe Biotechnology Co., Ltd., established on 2019-09-06, Business scope includes food,drinks,candy,Production of food additives,Sales(Including online sales);Biotechnology,food processing technology,feed technology,Technology research and development in the field of pharmaceutical intermediates,technical consulting,technology transfer,Technical Services;cosmetic,Daily necessities,Edible produce,organic fertilizer,microbial fertilizer,Pharmaceutical Intermediates,household appliances,electronics sales;Research and development of feed and feed additives,Production,Sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)